<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02576639</url>
  </required_header>
  <id_info>
    <org_study_id>CCNP520X2102</org_study_id>
    <secondary_id>2013-005576-18</secondary_id>
    <nct_id>NCT02576639</nct_id>
  </id_info>
  <brief_title>Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will determine the safety of CNP520 in healthy elderly over 3 months. Data
      relevant for Pharmacokinetic/Pharmacodynamic modeling will be obtained in order to define
      the target dose in subsequent efficacy studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and deaths</measure>
    <time_frame>Date of enrollment until about 30 days after last dose</time_frame>
    <description>Adverse event and will be evaluated with respect to multiple aspects including incidence, time course, severity, relationship to drug intake etc. Other safety data will be primarily evaluated with respect to out-of-range values and trends over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Aβ, Aβ 1-40 and Aβ 1-42 concentrations in CSF</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>Change from baseline of Aβ concentrations in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNP520 concentrations in CSF</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>This outcome measures the CNP520 concentrations in CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>CNP520 concentrations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area-under-plasma concentration time curve up to infinity (AUCinf)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>CNP520 concentrations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area-under-plasma concentration time curve during dosing interval (AUCtau)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>CNP520 concentrations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
    <description>CNP520 concentrations in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent oral clearance (Cl/F)</measure>
    <time_frame>Predose through study completion (6months)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CNP520 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 healthy elderly subjects will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNP520 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 healthy elderly subjects will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNP520 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 healthy elderly subjects will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CNP520 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 healthy elderly subjects will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 healthy elderly subjects will be enrolled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNP520</intervention_name>
    <description>CNP520 will be taken oral, once-daily for 13 weeks</description>
    <arm_group_label>CNP520 Dose 1</arm_group_label>
    <arm_group_label>CNP520 Dose 2</arm_group_label>
    <arm_group_label>CNP520 Dose 3</arm_group_label>
    <arm_group_label>CNP520 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study is placebo controlled</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy status

          -  Body weight: ≥45kg

          -  BMI: 18-34 kg/m2

        Key Exclusion Criteria:

          -  History or presence of any clinically significant disease of any major system organ
             class.

          -  Heavy smoker status

          -  History /presence of clinically significant neurological or psychiatric disorders

          -  Any medical condition that might lead to or is associated with any cognitive deficit

          -  History or presence of severely impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <state>AG</state>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mid Glamorgan</city>
        <zip>CF484DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 3, 2016</lastchanged_date>
  <firstreceived_date>August 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease,</keyword>
  <keyword>Amyloid Beta,</keyword>
  <keyword>cerebrospinal fluid,</keyword>
  <keyword>beta secretase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
